NCT01897012 - Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 17, 2013

Primary Completion Date

October 31, 2018

Study Completion Date

November 30, 2018

Conditions

MYC PositiveRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Hodgkin LymphomaRecurrent Mantle Cell LymphomaRecurrent Mature T- and NK-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Burkitt LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory Hodgkin LymphomaRefractory Mantle Cell LymphomaRefractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

Interventions

DRUG

Alisertib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Romidepsin

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH